Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

被引：0

作者：

Jonasch, Eric ^{[1
]}

Call, Justin ^{[2
]}

Kambhampati, Swetha ^{[3
]}

Caimi, Paolo ^{[4
]}

Curti, Brendan ^{[5
]}

Diefenbach, Catherine ^{[6
]}

Heath, Elisabeth ^{[7
]}

Park, Steven ^{[8
]}

Kornblum, Noah ^{[9
]}

Li, Weidong ^{[10
]}

Reimers, Melissa ^{[11
]}

Spurgeon, Stephen ^{[12
]}

Vaishampayan, Ulka ^{[13
]}

Ye, Dingwei ^{[14
]}

Zhang, Li ^{[15
]}

Zhao, Weili ^{[16
]}

Chen, Zhu ^{[17
]}

Hunder, Naomi ^{[17
]}

Ma, Sharon ^{[17
]}

Song, Eric ^{[17
]}

Garmezy, Benjamin ^{[18
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dallas, TX USA

[2] START Mt Region, West Valley, UT USA

[3] City Hope Comprehens Canc Ctr, Duarte, CA USA

[4] Cleveland Clin Fdn, Cleveland, OH USA

[5] Providence Canc Inst, Providence Portland Med Ctr, Providence, RI USA

[6] NYU Langone Hlth, New York, NY USA

[7] Hudson Webber Canc Res Ctr, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[8] Levine Canc Inst, Charlotte, NC USA

[9] Montefiore Med Ctr, Bronx, NY USA

[10] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Oregon Hlth & Sci Univ, Portland, OR USA

[13] Univ Michigan, Ann Arbor, MI USA

[14] Fudan Univ, Shanghai Canc Hosp, Shanghai, Peoples R China

[15] Sun Yat Sen Univ, Canc Cetr, Guangzhou, Peoples R China

[16] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China

[17] ProfoundBio US Co, Woodinville, WA USA

[18] Sarah Cannon Res Inst, Tennessee Oncol, London, England

来源：

ONCOLOGIST | 2023年 / 28卷

关键词：

C-0+ZFASDFD70; ADC; antibody-drug conjugate; exatecan; NHL; renal cell carcinoma; nasopharyngeal carcinoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[1] PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma
Wang, Lei
Liu, Haidong
Shang, Xiao
Han, Tae
Zhao, Baiteng
CANCER RESEARCH, 2022, 82 (12)
[2] Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
Call, Justin
Orr, Douglas
Anderson, Ian
Richardson, Debra L.
Chen, Zhu
Ma, Sharon
Hunder, Naomi N.
Hamilton, Erika
CANCER RESEARCH, 2023, 83 (08)
[3] Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
Call, Justin A.
Orr, Douglas W.
Anderson, Ian Churchill
Richardson, Debra L.
Chen, Zhu
Ma, Sharon
Hunder, Naomi N. H.
Hamilton, Erika P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
Tolcher, A. W.
Calvo, E.
Maitland, M. L.
Gibson, B.
Xuan, D.
Joh, T.
Jackson-Fischer, A.
Damelin, M.
Barton, J.
Xin, X.
Sachdev, J. C.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
[5] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors
Wang, Jiani
Tong, Zhongsheng
Tan, Yinuo
Shi, Yehui
Wu, Yun
Zhou, Qing
Xing, Xiaoyan
Chen, Xiaomei
Qiu, Fuming
Ma, Fei
CELL REPORTS MEDICINE, 2024, 5 (09)
[6] A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
Schoffski, Patrick
Concin, Nicole
Suarez, Cristina
Subbiah, Vivek
Ando, Yuichi
Ruan, Shiling
Wagner, Joel P.
Mansfield, Keith
Zhu, Xu
Origuchi, Shizuka
DiDominick, Sarah
Bialucha, Carl U.
Faris, Jason E.
Tran, Ben
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (10) : 547 - 556
[7] POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.
Li, H.
Han, T. H.
Hunder, N.
Jang, G.
Zhao, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S41 - S42
[8] EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES
Han, T. H.
Grove, L. E.
Lynch, C. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S17 - S18
[9] A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
Wang, Jie
Wu, Lin
Song, Zhengbo
Li, Xingya
Liu, Caigang
Liu, Tianshu
Wu, Yiwen
Zhang, Ze
Wang, Shuni
CANCER RESEARCH, 2023, 83 (08)
[10] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
Lopez, Diana M.
Barve, Minal
Wang, Judy
Bullock, Andrea J.
Pectasides, Eirini
Vaishampayan, Ulka
Spira, Alexander I.
Ulahannan, Susanna
Patnaik, Amita
Sanborn, Rachel E.
Cicic, Dragan
Ang, Qiuqing
Bergonio, Gregory
Ahnert, Jordi Rodon
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)

← 1 2 3 4 5 →